跳至主要内容
临床试验/NCT04932070
NCT04932070已完成不适用

Berberine is an Effective Insulin Sensitizer and Improves Homeostasis of Metabolic and Hormonal Disorders in Women With Polycystic Ovary Syndrome: a Novel Treatment Strategy for PCOS

Azienda di Servizi alla Persona di Pavia2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2020年9月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
Changes on insulin resistance

研究概览

简要总结

Polycystic Ovary Syndrome (PCOS) is the most frequent endocrine disease in female reproductive-age. Recently, increasing evidence has shown that natural plant-based products may play a role in PCOS management. Previous study in PCOS preclinical model and in humans demonstrated that berberine is an effective insulin sensitizer and improves homeostasis of metabolic, inflammatory and hormonal disorders. However, to date there is no clinical study that considers globally all the activities carried out by berberine in PCOS clinical features. Given this background, aim of this study was to evaluate in normal-overweight PCOS women with normal menses the berberine effectiveness on: insulin resistance by Homeostasis Model Assessment (HOMA); inflammation by C-Reactive Protein (CRP), TNF-alpha; lipid metabolism; sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); body composition by dual-energy X-ray absorptiometry. All these parameters were collected at baseline and 60 days after supplementation with a new bioavailable and safe berberine formulation. Finally, adverse effects were assessed by liver and kidney functions. To evaluate statistically significant pre- post-supplementation changes, fitted a linear mixed model for each investigated endpoint was performed.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • normal and overweight women (Body Mass Index (BMI) 25-30 kg/m2)
  • newly detected Polycystic Ovary Syndrome

排除标准

  • any concomitant medication
  • presence of liver, renal and thyroid disease
  • drinking more than two standard alcoholic beverages/day (20 g of alcohol/day)

结局指标

主要结局

Changes on insulin resistance

时间窗: Changes from baseline insulin resistance at 8 weeks

Homeostasis Model Assessment (pt), for evaluate insulin resistance if \> 2.4

次要结局

  • Changes on lipid profile(Changes from baseline lipid profile at 8 weeks)
  • Changes on Hormonal profile(Changes from baseline Hormonal profile at 8 weeks)
  • Changes on body composition(Changes from baseline body composition at 8 weeks)
  • Changes on inflammation(Changes from baseline inflammation at 8 weeks)
  • Changes on Carbohydrate profile(Changes from baseline Carbohydrate profile at 8 weeks)
  • Changes on safety(Changes from baseline safety at 8 weeks)
  • Changes on anthropometry(Changes from baseline anthropometry at 8 weeks)
  • Changes on acne assessment(Changes from baseline acne assessment at 8 weeks)

研究者

发起方
Azienda di Servizi alla Persona di Pavia
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验